Epidemiology of Inflammatory Markers and CHD: Evidence for High-Sensitivity C-Reactive Protein Paul M. Ridker, MD, MPH.

Slides:



Advertisements
Similar presentations
Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.
Advertisements

Emerging Cardiac Risk Factors Jon W. Wahrenberger, MD FACC DHMC Cardiology Update Symposium 2003 December 1, 2003.
Acute Coronary Syndromes and The Inflammation Theory: Fact or Fiction Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Saint-Joseph University.
© Copyright 2009 by the American Association for Clinical Chemistry LOX Index, a Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
New concepts and guidelines in the management of LDL-c and CV Risk: Need for early intervention Prof. Ulf Landmesser University Hospital Zürich Switzerland.
Inflammation, Thrombosis, Infection, and CARDIOVASCULAR DISEASE Nathan D Wong, PhD, FACC Professor and Director Heart Disease Prevention Program University.
Slide Source LipidsOnline CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Presenter Disclosure Information Diane Bild, MD, MPH Screening for Subclinical Atherosclerosis as a Strategy for CVD Prevention FINANCIAL DISCLOSURE: None.
Cardiovascular Risk Factor Overview and Management
Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)
Slide Source: Lipids Online Inflammation and CHD Inflammation and CHD Nathan Wong.
C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive Cardiology Nathan D. Wong, PhD, FACC, FAHA Professor and Director.
Slide Source: Lipids Online Plasma Concentration of TNF- and Risk of Recurrent Coronary Events –2.47 (1 st –50 th.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,
Global impact of ischemic heart disease World Heart Federation, 2011.
Cost-Effectiveness of hsCRP Screening 1. Adjunct to Global Risk Assessment 2. Method to Monitor Statin Efficacy in Secondary Prevention 3. Method to Target.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
© Copyright 2009 by the American Association for Clinical Chemistry Plasma Myeloperoxidase Predicts Incident Cardiovascular Risks in Stable Patients Undergoing.
Atherosclerosis Part 1 Atherosclerosis The general term for hardening of the arteries The most prevalent form of atherosclerosis is characterized by the.
Inflammatory Markers, Pharmacotherapy, and Clinical Trials Paul M. Ridker, M.D., M.P.H., and Christie M. Ballantyne, M.D.
Wolfgang Koenig, MD, FESC, FACC Dept. of Internal Medicine II - Cardiology University of Ulm Medical Center Ulm, Germany CRP, Lp-PLA 2, and Other Serum.
AHA- Nov 12, 2005, Dallas P.K.Shah, MD Director of Cardiology and Atherosclerosis Research Center, Cedars-Sinai Medical Center, Professor of Medicine,
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Introduction Lipoprotein(a) [Lp(a)]
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
Landmark clinical trials with pravastatin WOS CARE LIPID.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.
Slide Source: Lipids Online Slide Library LDL Cholesterol, mg/dL Years of Follow-up Ridker PM et al. N Engl J Med 2002;347:1557–1565.
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Slide Source: Lipids Online Slide Library C-Reactive Protein, Metabolic Syndrome, and Risk for CV Events: Women’s Health Study 14,719.
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
20 Cardiovascular Disease and Physical Activity chapter.
Chapter 14 Patterns in Health and Disease: Epidemiology and Physiology EXERCISE PHYSIOLOGY Theory and Application to Fitness and Performance, 6th edition.
Controversial Pathophysiologic Contributors to Acute MI and Atherosclerosis Atherothrombotic events occur in individuals without readily apparent risk.
순환기질환 - 혈관, 림프관 -.
Are We There Yet ? Abdul H. Sankari, MD FACC FCCP.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Cardiovascular Disease: Risk Factors and Risk Assessment
The role of unknown risk factors in coronary heart disease
Results from the intermountain heart collaborative study
Elevated Circulating Levels of Inflammatory Markers in
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Cardiovascular Disease Risk in Patients with Rheumatic Diseases
AHA 2017 Residual Inflammatory Risk and Residual Cholesterol Risk:
HDL cholesterol and cardiovascular risk Epidemiological evidence
CANTOS: The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
HDL cholesterol and cardiovascular risk
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
The following slides highlight a report on a presentation at the Canadian Cardiovascular Congress held in Toronto, Ontario from October 24 to 29, 2003.
A: Epidemiology update
Type 2 diabetes: Overlap of clinical conditions
Advanced Nutrition Diet and Cardiovascular Disease 1
Hyperlipidemia: A well-documented modifiable risk factor for stroke
OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.
To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B?  Carl J. Lavie, MD, Richard V. Milani, MD, James.
Circulatory System.
Distribution of Cardiovascular Risk Factors by Baseline CRP Concentration M. Cushman et al. Circulation. 2005;112:25-31.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
ACC 2018 Orlando, Florida Interleukin-1b Inhibition with Canakinumab and Cardiovascular Event Reduction Among Patients with Moderate Chronic Kidney Disease.
Presentation transcript:

Epidemiology of Inflammatory Markers and CHD: Evidence for High-Sensitivity C-Reactive Protein Paul M. Ridker, MD, MPH

Beyond Cholesterol: Predicting Cardiovascular Risk In the 21 st Century Cardiovascular Risk Lipids HTN Diabetes BehavioralBehavioral Hemostatic Thrombotic InflammatoryInflammatoryGeneticGenetic

Total Cholesterol Distribution: CHD vs Non-CHD Population Castelli WP. Atherosclerosis. 1996;124(suppl):S1-S9. 1996 Reprinted with permission from Elsevier Science. 35% of CHD Occurs in People with TC<200 mg/dL Total Cholesterol (mg/dL) No CHD CHD Framingham Heart Study—26-Year Follow-up

Inflammation and Atherosclerosis Inflammation may determine plaque stability - Unstable plaques have increased leukocytic infiltrates - T cells, macrophages predominate rupture sites - Cytokines and metalloproteinases influence both stability and degradation of the fibrous cap Lipid lowering may reduce plaque inflammation - Decreased macrophage number - Decreased expression of collagenolytic enzymes (MMP-1) - Increased interstitial collagen - Decreased expression of E-selectin - Reduced calcium deposition Libby P. Circulation 1995;91: Ross R. N Engl J Med 1999;340:

Is there clinical evidence that inflammatory markers predict future coronary events and provide additional predictive information beyond traditional risk factors?

hs-CRP and Risk of Future MI in Apparently Healthy Men Ridker PM et al. N Engl J Med 1997;336: <0.055 Relative Risk of MI P = 0.03 Quartile of hs-CRP (range, mg/dL) – – >0.211 P < P Trend <0.001

hs-CRP and Risk of Future MI: Analysis Stratified by Smoking Status Ridker PM et al. N Engl J Med 1997;336: Relative Risk of Future MI Quartile of CRP 234 All Patients Nonsmokers

hs-CRP and Risk of Future MI: Analysis Stratified by Year of Follow-up Ridker PM et al. N Engl J Med 1997;336: 1997 Massachusetts Medical Society. All rights reserved. 0 – 2 Relative Risk (per Quartile) Years of Study Follow-up 2 – 44 – 66+

hs-CRP and Risk of Future Stroke in Apparently Healthy Men Ridker PM et al. N Engl J Med 1997;336: <0.055 Relative Risk of Ischemic Stroke Quartile of hs-CRP (range, mg/dL) – – >0.211 P =0.02 P Trend <0.03

hs-CRP and Risk of Developing PVD in Apparently Healthy Men Ridker PM et al. Circulation 1998;97: 1998 Lippincott Williams & Wilkins. None hs-CRP (mg/dL) Intermittent Claudication Peripheral Artery Surgery

hs-CRP and Risk of Future Cardiovascular Events in Apparently Healthy Women Ridker PM et al. Circulation 1998;98: <0.15 Relative Risk Quartile of hs-CRP (range, mg/dL) – – >0.73 P Trend <0.002 Any Event MI or Stroke

hs-CRP and Risk of Future Cardiovascular Events in Apparently Healthy Women: Low-Risk Subgroups Ridker PM et al. Circulation 1998;98: <0.15 Relative Risk Quartile of hs-CRP (range, mg/dL) – – >0.73 No hypertension No hyperlipidemia No current smoking No diabetes No family history

hs-CRP and Coronary Heart Disease in Initially Healthy Men: MONICA–Augsburg Cohort Koenig W et al. Circulation 1999;99: <0.6 Rate Ratio (Age Adjusted) Quartile of CRP (mg/dL) 2 0.6– – –4.5 5 >4.5

hs-CRP as a Risk Factor for Future CVD Relative Risk (upper vs lower quartile) CHD Death MI Stroke CHD PVD CVD CHD 0 MRFIT ( Kuller 1996) PHS (Ridker 1997) CHS/RHPP (Tracy 1997) PHS (Ridker 1998) WHS (Ridker 1998, 2000) MONICA (Koenig 1999) Helsinki (Roivainen 2000) Caerphilly (Mendall 2000) Britain (Danesh 2000)

hs-CRP Adds to the Predictive Value of Total Cholesterol in Determining Risk of First MI Ridker PM et al. Circulation 1998;97: 1998 Lippincott Williams & Wilkins. Adjusted Relative Risk CRP >75 th percentile TC >75 th percentile –+–+ –+–+ P = 0.02 P = P = 0.002

hs-CRP Adds to Predictive Value of TC:HDL Ratio in Determining Risk of First MI Ridker PM et al. Circulation 1998;97: 1998 Lippincott Williams & Wilkins. Total Cholesterol:HDL Ratio hs-CRP

Quartile of TC: HDL-C Quartile of hs-CRP hs-CRP, Lipids, and Risk of Future Coronary Events: Women's Health Study (WHS) Ridker PM et al. N Engl J Med 2000;342:

Relative Risks for First MI for Baseline sICAM-1 >260 ng/dL Ridker PM et al. Lancet 1998;351: 1998 Reprinted with permission from Elsevier Science. Years of Study Follow-up 0– –22–44–8 Relative Risk

Predictivity of Interleukin-6 on CV Risk in Women Ridker PM et al. N Engl J Med 2000;342: 2000 Massachusetts Medical Society. All rights reserved High Medium Low High Medium Low Interleukin-6 Total cholesterol

Plasma Concentration of TNF- and Risk of Recurrent Coronary Events Ridker PM et al. Circulation 2000;101: 2000 Lippincott Williams & Wilkins –2.47 (1 st –50 th ) Relative Risk TNF- Concentration, pg/mL (percentile of control distribution) 2.48–3.05 (51 st –75 th ) 3.06–4.17 (76 th –95 th ) (>95 th )

Risk Factors for Future Cardiovascular Events: WHS Relative Risk of Future Cardiovascular Events 0 Ridker PM et al. N Engl J Med 2000;342: Lipoprotein(a) Homocysteine IL-6 TC LDL-C sICAM-1 SAA Apo B TC:HDL-C hs-CRP hs-CRP + TC:HDL-C

Predictive Value of CRP and Other Inflammatory Markers: LDL <130 mg/dL Ridker PM et al. N Engl J Med 2000;342: Relative Risk of Future Coronary Events Quartile of Inflammatory Marker hs-CRP 234 SAA IL-6 sICAM-1

Potential Mechanisms Linking CRP to Atherothrombosis Confounding by cigarette consumption Innocent bystander - Acute phase response Cytokine surrogate - IL-6, TNF-, IL-1 Direct effects of CRP - Innate immunity - Complement activation - CAM induction Prior infection - Chlamydia, H pylori, CMV Marker for subclinical atherosclerosis - EBCT / IMT / ABI Marker for insulin resistance/ obesity Marker for endothelial dysfunction Marker for dysmetabolic syndrome Marker for plaque vulnerability

Evaluating Novel Risk Factors for CAD Consistency of prospective data Strength of association Independence of association Improve predictive value Standardized measure Low variability High reproducibility Biologic plausibility Low cost Modifiable

CRP vs hs-CRP CRP is an acute-phase protein produced by the liver in response to cytokine production (IL-6, IL-1, tumor necrosis factor) during tissue injury, inflammation, or infection. Standard CRP Standard CRP tests determine levels which are increased up to 1,000-fold in response to infection or tissue destruction, but cannot adequately assess the normal range High-sensitivity CRP High-sensitivity CRP (hs-CRP) assays (i.e. Dade Behring) detect levels of CRP within the normal range, levels proven to predict future cardiovascular events.

hs-CRP: Automated Commercial Latex- Enhanced Assay (Dade) vs Validated in- House ELISA Dade hs-CRP (Latex, In[mg/L]) hs-CRP (ELISA, In[mg/L]) (In-house) Rifai N et al. Clin Chem 1999;45: r = 0.93 P < 0.001

Age-Adjusted Correlation Coefficients for hs-CRP Levels and Lipid Parameters over a 5-Year Follow-up Period ParameterrP hs-CRP Total Cholesterol LDL-C HDL-C Triglycerides Ridker PM et al. Circulation 1999;100:

Population Distribution of hs-CRP in Apparently Healthy American Men and Women QuintileRange (mg/dL)Risk Estimate 10.01–0.069Low 20.07–0.11Mild 30.12–0.19Moderate 40.20–0.38High 50.39–1.50Highest Ridker PM et al. Circulation. In press.

Biomarkers for Venous and Arterial Thrombosis ParameterVenousArterial Fibrinogen–+++ Factor VII–+ vWF: ag–++ tPA: ag–+++ PAI-1: ag–++ Platelet function–++ Lp(a)–+ hs-CRP / SAA / IL-6 / TNF–+++

Biomarkers for Venous and Arterial Thrombosis (cont’d) ParameterVenousArterial Factor V Leiden+++– Prothrombin mutation++– Prothrombin+– Factor VIII++– Anti-thrombin III++– Protein C+– Protein S+– Homocysteine++ D-dimer++

Assessment of the Clinical Utility of Novel Markers of Cardiovascular Risk Marker Assay Conditions Standardized? Prospective Studies Consistent? Additive to TC and HDL- C? Lp(a)–+/– Homocysteine++/– tPA and PAI-1+/–+ Fibrinogen+/–++ hs-CRP+++ Ridker PM et al. Ann Intern Med 1999;130: